Dr. Amit Kumar Jain Medical Oncologist & Hematologist

The record

Publications & trials

18 peer-reviewed publications and 21 Phase III/IV international clinical trials, listed in full.

The record

The record, kept whole:
18 publications and 23 trial enrolments.

Peer-reviewed oncology in indexed international journals, presented at national and international meetings, and enrolled as sub-investigator across Phase III/IV trials. Everything below is listed in full, most recent first.

18

Peer-reviewed publications

23

International trial enrolments

7

Conference papers & posters

1

Awards and honours

01Publications

Peer-reviewed publications

18 original research articles and case reports, most recent first, in indexed international journals.

  1. 18

    Jain AK, Parikh P, Dadhich SC, Arora A, Kumar M, Ranjan P, et al.

    Familial Polyposis and Colon Cancer

    South Asian J Cancer 2024;13:305–8

    PubMed Central · DOAJ Indexed

  2. 17

    Jain AK.

    Oral Cancer Screening: Insights into Epidemiology, Risk Factors, and Screening Programs for Improved Early Detection

    Cancer Screen Prev 2024;3(2):97-105

    Google Scholar Indexed

  3. 16

    Jain AK.

    Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological parameters and molecular imaging

    Indian J. Surg. Oncol. 2023;14:279-87

    Scopus Indexed

  4. 15

    Jain AK.

    Oncological Emergencies. In: Richhariya D, editor. Text Book of Emergency Medicine including intensive care & Trauma, 2nd ed. New Delhi: Jaypee brothers medical publishers; 2022. p. 967-78.

    Book Chapter — Jaypee

    Book Chapter · Jaypee

  5. 14

    Nair RR, Singh PK, Sharma J, Gambhir I, Khanna S, Jain AK, et al.

    An Unusual Case of Pancytopenia: Lessons Learnt

    Indian J Crit Care Med 2022;26(1):141–4

    PubMed Central · Embase · Scopus Indexed

  6. 13

    Jain AK, Bhat G, Gupta VG, Goyal H.

    Liquid Biopsy

    Indian J Med Paediatr Oncol 2021;42:77-9

    Scopus Indexed

  7. 12

    Goyal H, Khetarpal A, Jain AK.

    A case of accidental vincristine overdose and effective use of therapeutic plasma exchange in its management

    Indian J Med Paediatr Oncol 2020;41:770-2

    Scopus Indexed

  8. 11

    Bhat G, Jain AK.

    Next generation sequencing

    Indian J Med Paediatr Oncol 2020;41:381-2

    Scopus Indexed

  9. 10

    Jain AK, Nandy P.

    Breast cancer prevention and management: Evidence and possibility in India

    Muller J Med Sci Res 2019;10:33-5

    DOAJ Indexed

  10. 9

    Jain AK, Nandy P.

    Clinico-Etiological Profile of Hyponatremia among Elderly Age Group Patients in a Tertiary Care Hospital in Sikkim

    J Family Med Prim Care 2019;8:988-94

    PubMed Central Indexed

  11. 8

    Rishi, Jain AK, Nandy P.

    Study of clinical, laboratory, and upper gastrointestinal endoscopic profile in patients of alcoholic liver disease in Sikkim

    Med J DY Patil Vidyapeeth 2018;11:228-31

    DOAJ Indexed

  12. 7

    Jain AK, Khatri D, Theengh DP, Nandy P.

    Clinico-epidemiological profile of haemodialysis patients in a teaching hospital in North Eastern India

    Int J Sci Res 2018;7:15-8

    Indian Citation Index · Index Medicus

  13. 6

    Theengh DP, Yadav P, Jain AK, Nandy P.

    Assessment of metabolic syndrome in HIV infected individuals

    Indian J Sex Transm Dis 2017;38:152-6

    PubMed Central Indexed

  14. 5

    Lepcha LS, Jain AK, Nandy P.

    Sociodemographic profile and treatment outcome of tuberculosis patients registered under directly observed treatment short course in East Sikkim with reference to defaulters

    J Med Soc 2017;31:147-51

    Embase Indexed

  15. 4

    Suresh M, Srivastava NK, Jain AK, Nandy P.

    Thyroid dysfunction in critically ill patients in a tertiary care hospital in Sikkim

    Thyroid Res Pract 2017;14(2):58-62

    Index Copernicus Indexed

  16. 3

    Gupta S, Jain AK, Khandelwal B, Nandy P.

    Case of New Onset Bochdalek's Hernia in Adult: Is it Thalidomide Induced?

    Indian J Emerg Med 2016;2(2):141-3

    Index Copernicus Indexed

  17. 2

    Jain AK, Nandy P.

    A Solitary Anthracotic Lower Lobe Lung Mass Mimicking Lung Malignancy – An Unusual Presentation

    Egypt J Bronchol 2016;10(2):82

    Google Scholar Indexed

  18. 1

    Sinha R, Jain AK, Jagdhane N, Nandy P, Khanna SK.

    Moyamoya Disease Associated with Recurrent Right Thalamic Haemorrhage and Hydrocephalous: A Case Report

    Turk Neurosurg 2014;25(5):811-3

    Medline Indexed

02Conference papers

Conference papers & posters

Presented at national and international oncology and internal-medicine meetings.

  1. VII

    Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological parameters and molecular imaging

    ISMPOCON 2020, Bengaluru

  2. VI

    A case of accidental vincristine overdose and effective use of therapeutic plasma exchange in its management

    ISMPOCON 2020, Bengaluru

  3. V

    Prevalence of Microsatellite Instability among Gastrointestinal and Hepato-Pancreato-Biliary cancers at a tertiary care hospital in North India

    ICON 2018, Indore

  4. IV

    Study of clinico-epidemiological profile of haemodialysis patients in a tertiary care university hospital in North Eastern India

    ISNCON 2015, Bengaluru

  5. III

    Mushroom poisoning in Sikkim: A retrospective study

    APICON 2015, Gurgaon

  6. II

    Thyroid dysfunction in critically ill patients in a tertiary care hospital in Sikkim

    EZ-APICON 2014, Guwahati

  7. I

    Clinico-Etiological Profile of Hyponatremia among Elderly Age Group Patients in a Tertiary Care Hospital in Sikkim

    IACMCON 2014, Siliguri

03Awards

Awards & recognition

  • Second Place, Paper Presentation

    West Bengal chapter of IACMCON 2014, Siliguri.

04Clinical trials

Clinical trials

Sub-investigator on 21 Phase III/IV international clinical trials, grouped by tumour site.

Breast Oncology

7 trials

  • HER2+ Metastatic Breast Cancer

    Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer

    Sub-Investigator

  • Trastuzumab Emtansine (T-DM1)

    Phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane

    Sub-Investigator

  • Abemaciclib Adjuvant (monarchE)

    Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer

    Sub-Investigator

  • TX05 vs Herceptin

    Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of TX05 With Herceptin® in Subjects With HER2 Positive Early Breast Cancer

    Sub-Investigator

  • CapItello290 (TNBC)

    Phase III Trial Assessing the Efficacy and Safety of Capivasertib + Paclitaxel as First-line Treatment for Patients with Locally Advanced or Metastatic TNBC

    Sub-Investigator

  • Abemaciclib (MonarchE)

    Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in High Risk, Node Positive, Early Stage BC

    Sub-Investigator

  • Giredestrant (lidERA)

    Phase III Study Evaluating the Efficacy and Safety of adjuvant Giredestrant compared with Physician's Choice of Adjuvant Endocrine Monotherapy in ER+/HER2- Early BC

    Sub-Investigator

Lung & Respiratory

7 trials

  • VEGF + Pemetrexed/Carboplatin

    Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC)

    Sub-Investigator

  • NEPTUNE (MEDI4736 + Tremelimumab)

    Phase III Global Study of MEDI4736 in Combination with Tremelimumab Versus Standard Platinum-Based Chemotherapy in First-Line Treatment of Advanced NSCLC

    Sub-Investigator

  • Lorlatinib vs Crizotinib (ALK+)

    Phase 3 Study of Lorlatinib monotherapy versus Crizotinib monotherapy in the first-line treatment of patients with advanced ALK-positive NSCLC

    Sub-Investigator

  • KEYNOTE-593 (Pembrolizumab India)

    Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with PD-L1 positive Non-small Cell Lung Cancer in India

    Sub-Investigator

  • LAURA (Osimertinib Maintenance)

    Phase III Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive NSCLC

    Sub-Investigator

  • AEGEAN (Durvalumab Neoadjuvant)

    Phase III Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer

    Sub-Investigator

  • KontRASt-02 (KRAS G12C)

    Phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant NSCLC

    Sub-Investigator

GI & Genitourinary

4 trials

  • VEGF + mFOLFOX6 (mCRC)

    Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer

    Sub-Investigator

  • Atezolizumab (Urothelial)

    Open Label, Safety Study of Atezolizumab In Locally Advanced Or Metastatic Urothelial Or Non-Urothelial Carcinoma Of The Urinary Tract

    Sub-Investigator

  • HIMALAYA (HCC)

    Phase III Study of Durvalumab and Tremelimumab as first-line Treatment in Patients with Unresectable Hepatocellular Carcinoma

    Sub-Investigator

  • NILE (Urothelial)

    Phase III Study of First-Line Durvalumab + Tremelimumab + SOC Chemotherapy Versus Standard of Care Alone in Unresectable Locally Advanced or Metastatic Urothelial Cancer

    Sub-Investigator

Gynae & Others

5 trials

  • Head & Neck (MEDI4736 + Tremelimumab)

    Phase III Global Study of MEDI4736 + Tremelimumab versus Standard of Care in First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients

    Sub-Investigator

  • CALLA (Cervical Cancer)

    Phase III Study to Determine the Efficacy and Safety of Durvalumab following Chemoradiotherapy in Women With Locally Advanced Cervical Cancer

    Sub-Investigator

  • KEYNOTE-593 (Melanoma India)

    Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma in India

    Sub-Investigator

  • FLORA-5 (Ovarian)

    Phase 3 Study comparing Chemo-Immunotherapy versus Chemotherapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

    Sub-Investigator

  • Levonadifloxacin (Immunocompromised)

    IIS study for evaluation of efficacy and safety of Levonadifloxacin for Gram-Positive Bacterial Infection in Immunocompromised patients

    Sub-Investigator

05Appointment

Consultations & second opinions

Appointments are held at Bhagwan Mahaveer Jain Hospital, Vasanth Nagar, Bengaluru. Bring prior records, imaging and histopathology reports for a productive first visit.

Request appointment Explore expertise
WhatsApp